Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Net Cash Flow (2020 - 2025)

BioAtla's Net Cash Flow history spans 6 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 83.91% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$41.9 million, up 32.83%, while the annual FY2025 figure was -$41.9 million, 32.83% up from the prior year.
  • Net Cash Flow reached -$1.2 million in Q4 2025 per BCAB's latest filing, up from -$9.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $62.3 million in Q3 2021 to a low of -$30.8 million in Q1 2024.
  • Average Net Cash Flow over 5 years is -$11.6 million, with a median of -$17.3 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: crashed 7206.45% in 2021, then skyrocketed 249.87% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$24.9 million in 2021, then surged by 249.87% to $37.4 million in 2022, then tumbled by 179.74% to -$29.8 million in 2023, then surged by 74.94% to -$7.5 million in 2024, then skyrocketed by 83.91% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Net Cash Flow are -$1.2 million (Q4 2025), -$9.9 million (Q3 2025), and -$14.2 million (Q2 2025).